Request for Applications (RFA) 
2018-2019 International Research Grants: Collagen VI, LAMA2, SEPN1 
Application Due Date: Friday 19th January 2018, 11:59 pm (local time)

Cure CMD 2018-2019 RFA (.pdf) 

Cure CMD Grant Application (.doc)

Cure CMD Grant Application (.pdf)

Cure CMD Grant Guidelines (.pdf)

Cure CMD Grant Policy (.pdf)

 

Cure CMD is pleased to announce availability of research funding for three grants, one for each of three specific CMD subtypes: Collagen VI; LAMA2 (Merosin) and SEPN1 (SELENON).


Note: each CMD subtype constitutes one competing application for Research Project Awards independent of the other two subtypes. 


2018-2019 Funding Opportunities


Collagen VI: Research Grants for project duration of up to two years.  Cure CMD will cover any combination of salary and consumables up to a maximum of $25,000 per year. The purpose of this RFA is to promote discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. Areas of interest include, but are not limited to, understanding the cause of disease, understanding tissue-specific phenotypes, unraveling pathways involved in disease, identifying novel drug targets or gene therapies, and testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline). In addition, applications may propose to create or improve disease models (e.g. animal models, patient-derived cell models), biomarkers or functional outcome measures to asses’ therapeutic impact.


LAMA2 (Merosin): Research Grants for project duration of up to two years.  Cure CMD will cover any combination of salary and consumables up to a maximum of $25,000 per year. The purpose of this RFA is to promote discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. Areas of interest include, but are not limited to, translational efforts for “linker” protein strategies, understanding the cause of disease, unraveling pathways involved in disease, identifying novel drug targets or gene therapies, and testing new strategies to treat disease or any of its detrimental consequences (e.g. fibrosis, seizures, respiratory function decline). In addition, applications may propose to create patient-derived cell models/assays development or systematic biomarker discovery or functional outcome measures validation to asses’ therapeutic impact.


SEPN1 (SELENON): Research Grants for project duration of up to two years.  Cure CMD will cover any combination of salary and consumables up to a maximum of $25,000 per year. The purpose of this RFA is to promote discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. Areas of interest include, but are not limited to, understanding the cause of disease, unraveling pathways involved in disease, identifying novel drug targets or gene therapies, and testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline). We also encourage applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), biomarkers or functional outcome measures to asses’ therapeutic impact.

Eligibility 

 

This opportunity is open to all international researchers. Applicants must hold a minimum academic position of Assistant Professor (US) or equivalent and hold a contract which extends beyond the duration of the proposed grant period. If you currently hold a Cure CMD funded project or were funded in the past, and have yet to submit your final progress report, you may still apply. In these cases, please attach progress report (maximum three pages) in order to continue eligibility.

How to Apply


Download the Cure CMD Grant Application, and carefully review Cure CMD’s Grant Guidelines and Grant Policy documents prior to completing the Grant Application form. Completed applications can be submitted via one of the following on or before Friday 19th January 2018, 11:59 pm (your local Institution time):


Email to: grants@curecmd.org 
File Upload: https://www.dropbox.com/request/QBsOXDGOSeq5bX6CX02D 


 

Joint Funding Opportunity with MDUK/Cure CMD for 2018 LMNA RFA

The purpose of this international invitation for LMNA-CMD research is to promote discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. We are particularly interested in receiving applications focused on unravelling pathways involved in skeletal muscle or cardiac muscle pathology, and identifying novel drug targets or gene therapies. In addition, applications may propose to create or improve disease models (e.g. animal models, patient-derived cell models), biomarkers or functional outcome measures to assess therapeutic impact.


For more information about this LMNA funding opportunity: Please reach out via email to: ResearchGrants@musculardystrophyuk.org or by phone at 020 7803 4812.

 
 

Connect with Us

Cure CMD

19401 S. Vermont Avenue
Suite J100

Torrance, CA 90502 USA

About Us

Copyright © 2018 Cure CMD

Cure CMD is U.S. registered 501(c)(3) non-profit organization. Donations are tax deductible to the
extent allowable by law.  U.S. Federal Tax ID: 26-2640975